Sanofi Acquires Blueprint Medicines for $9.1 Billion

Sanofi to Acquire Blueprint Medicines Corporation for $9.1 Billion, Expanding Rare Disease Portfolio

Boston – Sanofi has moved to bolster its presence in the rare disease market by entering into an agreement to acquire Blueprint Medicines Corporation, a biopharmaceutical company based in the United States, for approximately $9.1 billion. The acquisition price includes a payment of $129.00 per share in cash to Blueprint shareholders, along with additional contingent value rights (CVRs) that may yield further payments based on future milestones.

As part of the deal, Blueprint shareholders will also be entitled to one non-tradeable CVR per share, which provides potential additional milestone payments of $2.00 and $4.00 upon the successful achievement of specified developmental and regulatory goals concerning the drug BLU-808. Including potential CVR payments, the total equity value of this acquisition amounts to approximately $9.5 billion on a fully diluted basis. The purchase price reflects a premium of about 27% over Blueprint’s closing stock price on May 30, 2025.

Details of the Acquisition

The transaction is structured as a cash tender offer, contingent upon regulatory approvals and majority shareholder tender acceptance. Should the acquisition proceed as planned, a wholly owned subsidiary of Sanofi will merge with Blueprint. Any outstanding shares not tendered in the offer will be converted into the same $129.00 cash and CVR arrangement.

To finance this acquisition, Sanofi intends to utilize existing cash reserves and take on new debt, explicitly indicating that the deal is not dependent on any financing conditions. The company anticipates concluding the acquisition in the third quarter of 2025, revealing that the transaction will not significantly alter its financial guidance for 2025.

Implications for Sanofi and Blueprint Medicines

The acquisition bolsters Sanofi’s portfolio in rare immunology diseases, incorporating Blueprint’s significant contributions, particularly through its approved medication Ayvakit/Ayvakyt (avapritinib), which is used to treat systemic mastocytosis (SM) in both the United States and the European Union. Additionally, the acquisition includes a variety of other medications within Blueprint’s advanced and early-stage development pipeline.

In recent financial performance, Ayvakit generated $479 million in net revenues for the year 2024 and around $150 million in the first quarter of 2025, demonstrating a year-on-year growth of more than 60% compared to the first quarter of the previous year.

Market Response and Legal Scrutiny

Despite the expected benefits of the acquisition, it has drawn the attention of former Louisiana Attorney General Charles C. Foti, Jr., Esq., along with the law firm Kahn Swick & Foti, LLC, who are currently investigating the proposed sale’s adequacy for Blueprint shareholders. This scrutiny comes amid increasing concerns about ensuring that shareholders are receiving fair value for their investments in light of the substantial acquisition price.

Conclusion

Overall, the acquisition of Blueprint Medicines Corporation by Sanofi marks a significant move in the biopharmaceutical sector, focusing on the expanding market of rare diseases. As the process unfolds in the coming months, the impact on both companies, their shareholders, and the market will become clearer.